GlassScriptPhysician profile
Kiron Nair
NPI 1114260445
$1,374.56
in general payments reported to CMS, 2019-2025
20 companies · $243 in 2025
The $243 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.04 · 2021: $36.53 · 2022: $369 · 2023: $197 · 2024: $486 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $814 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $814.16 |
| Education | $111.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $313.52 | 2022-2025 | Rybrevant, Erleada, Akeega |
| Eisai INC. | $231.06 | 2022-2024 | |
| Daiichi Sankyo INC. | $173.38 | 2022-2025 | Enhertu, Datroway |
| Astellas Pharma US INC | $98.00 | 2019-2025 | Padcev, Xospata, Vyloy |
| Lilly USA, LLC | $83.91 | 2022-2024 | Jaypirca, Verzenio |
| Karyopharm Therapeutics INC. | $69.13 | 2022-2023 | Xpovio |
| Gilead Sciences, INC. | $57.24 | 2022-2023 | Trodelvy |
| Ipsen Biopharmaceuticals, INC | $52.24 | 2022-2024 | Tazverik, Onivyde |
| Sobi, INC | $45.55 | 2025 | |
| Kite Pharma, INC. | $33.20 | 2023 | Yescarta |
| Abbvie INC. | $31.16 | 2025 | |
| Pfizer INC. | $27.22 | 2025 | |
| Taiho Oncology, INC. | $23.71 | 2025 | |
| Global Blood Therapeutics, INC. | $22.73 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.44 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $22.00 | 2024 | Rybrevant |
| Incyte Corporation | $21.75 | 2024 | Monjuvi |
| Celgene Corporation | $18.28 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $14.24 | 2023 | Imbruvica |
| Puma Biotechnology, INC. | $13.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kiron Nair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.